Derfor anbefales brug af doxazosin- depottabletter ikke (se afsnit 4. 4).
In patients 8/ 24 with severe hepatic impairment clinical experience is lacking and therefore the use of doxazosin prolonged release tablets is not recommended (see section 4.4).